Hepatic (Liver) Metastasis - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Hepatic (Liver) Metastasis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 61-page report is available in PDF from $2000.

Hepatic (Liver) Metastasis - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Hepatic (Liver) Metastasis - Pipeline Review, H1 2015’, provides an overview of the Hepatic (Liver) Metastasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatic (Liver) Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Hepatic (Liver) Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatic (Liver) Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatic (Liver) Metastasis Overview 7
Therapeutics Development 8
Pipeline Products for Hepatic (Liver) Metastasis - Overview 8
Pipeline Products for Hepatic (Liver) Metastasis - Comparative Analysis 9
Hepatic (Liver) Metastasis - Therapeutics under Development by Companies 10
Hepatic (Liver) Metastasis - Therapeutics under Investigation by Universities/Institutes 11
Hepatic (Liver) Metastasis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Hepatic (Liver) Metastasis - Products under Development by Companies 14
Hepatic (Liver) Metastasis - Products under Investigation by Universities/Institutes 15
Hepatic (Liver) Metastasis - Companies Involved in Therapeutics Development 16
BioCancell Therapeutics, Inc. 16
CytRx Corporation 17
Digna Biotech, S.L. 18
Gradalis Inc. 19
Incuron, LLC 20
Novartis AG 21
Phosplatin Therapeutics LLC 22
Targetome 23
Hepatic (Liver) Metastasis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Antibodies to Inhibit FRMD4A for Oncology - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BC-821 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cancer vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cell Therapy to Target CEA for Oncology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cyt-HiPoA - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DB-02901 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
mepacrine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Monoclonal Antibody Conjugated to Activate p53 for Hepatic Metastasis - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pasireotide - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
PT-112 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TGM-002 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TGM-003 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Hepatic (Liver) Metastasis - Recent Pipeline Updates 50
Hepatic (Liver) Metastasis…

For more information open Hepatic (Liver) Metastasis - Pipeline Review, H1 2015.


Original Article: Hepatic (Liver) Metastasis - Pipeline Review, H1 2015


More From BioPortfolio on "Hepatic (Liver) Metastasis - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...